Abstract

This article describes the pharmacology of approved parenteral anticoagulants. These include the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), fondaparinux, and danaparoid, as well as the direct thrombin inhibitors hirudin, bivalirudin, and argatroban. UFH is a heterogeneous mixture of glycosaminoglycans that bind to antithrombin via a unique pentasaccharide sequence and catalyze the inactivation of thrombin, factor Xa, and other clotting enzymes. Heparin also binds to cells and plasma proteins other than antithrombin causing unpredictable pharmacokinetic and pharmacodynamic properties and triggering nonhemorrhagic side effects, such as heparin-induced thrombocytopenia (HIT) and osteoporosis. LMWHs have greater inhibitory activity against factor Xa than thrombin and exhibit less binding to cells and plasma proteins than heparin. Consequently, LMWH preparations have more predictable pharmacokinetic and pharmacodynamic properties, have a longer half-life than heparin, and are associated with a lower risk of nonhemorrhagic side effects. LMWHs can be administered once daily or bid by subcutaneous injection, without coagulation monitoring. Based on their greater convenience, LMWHs have replaced UFH for many clinical indications. Fondaparinux, a synthetic pentasaccharide, catalyzes the inhibition of factor Xa, but not thrombin, in an antithrombin-dependent fashion. Fondaparinux binds only to antithrombin. Therefore, fondaparinux-associated HIT or osteoporosis is unlikely to occur. Fondaparinux exhibits complete bioavailability when administered subcutaneously, has a longer half-life than LMWHs, and is given once daily by subcutaneous injection in fixed doses, without coagulation monitoring. Three additional parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in patients with HIT.

Keywords

FondaparinuxBivalirudinHeparinMedicineArgatrobanAntithrombinDiscovery and development of direct thrombin inhibitorsPharmacologyThrombinPharmacodynamicsHirudinCoagulationPharmacokineticsAnticoagulantSurgeryImmunologyInternal medicineThrombosisPlateletVenous thromboembolism

MeSH Terms

AntithrombinsArginineChondroitin SulfatesDermatan SulfateDose-Response RelationshipDrugEvidence-Based MedicineFibrinolytic AgentsFondaparinuxHeparinHeparinLow-Molecular-WeightHeparitin SulfateHirudinsHumansInfusionsIntravenousPeptide FragmentsPipecolic AcidsPolysaccharidesPractice Guidelines as TopicRecombinant ProteinsSocietiesMedicalSulfonamidesThrombinThrombosisUnited States

Affiliated Institutions

Related Publications

Publication Info

Year
2012
Type
review
Volume
141
Issue
2
Pages
e24S-e43S
Citations
1029
Access
Closed

Social Impact

Altmetric

Social media, news, blog, policy document mentions

Citation Metrics

1029
OpenAlex
39
Influential
866
CrossRef

Cite This

David García, Trevor Baglin, Jeffrey I. Weitz et al. (2012). Parenteral Anticoagulants. CHEST Journal , 141 (2) , e24S-e43S. https://doi.org/10.1378/chest.11-2291

Identifiers

DOI
10.1378/chest.11-2291
PMID
22315264
PMCID
PMC3278070

Data Quality

Data completeness: 86%